Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example

被引:1
|
作者
Zheng, Shutao [1 ]
He, Shuo [1 ]
Liang, Yan [1 ]
Tan, Yiyi [1 ]
Liu, Qing [1 ]
Liu, Tao [2 ]
Lu, Xiaomei [1 ]
机构
[1] Xinjiang Med Univ, Clin Med Res Inst, State Key Lab Pathogenesis Prevent & Treatment Hig, Affiliated Hosp 1, Urumqi 830054, Xinjiang, Peoples R China
[2] Xinjiang Med Univ, Dept Clin Lab, Affiliated Hosp 1, Urumqi 830054, Xinjiang, Peoples R China
来源
MOLECULAR BIOMEDICINE | 2024年 / 5卷 / 01期
关键词
PI3K; PIK3CA; Mutation; Squamous cell carcinoma; Resistance; PI3K PATHWAY; HUMAN-PAPILLOMAVIRUS; ONCOGENIC MUTATIONS; GENE-MUTATIONS; HIGH-FREQUENCY; CANCER; HEAD; PROGNOSIS; RESISTANCE; OVEREXPRESSION;
D O I
10.1186/s43556-024-00176-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Compared with those in adenocarcinoma, PIK3CA mutations are more common in squamous cell carcinoma (SCC), which arises from stratified squamous epithelia that are usually exposed to adverse environmental factors. Although hotspot mutations in exons 9 and 20 of PIK3CA, including E542K, E545K, H1047L and H1047R, are frequently encountered in the clinic, their clinicopathological meaning remains to be determined in the context of SCC. Considering that few reviews on PIK3CA mutations in SCC are available in the literature, we undertook this review to shed light on the clinical significance of PIK3CA mutations, mainly regarding the implications and ramifications of PIK3CA mutations in malignant cell behavior, prognosis, relapse or recurrence and chemo- or radioresistance of SCC. It should be noted that only those studies regarding SCC in which PIK3CA was mutated were cherry-picked, which fell within the scope of this review. However, the role of mutated PIK3CA in adenocarcinoma has not been discussed. In addition, mutations occurring in other main members of the PI3K-AKT-mTOR signaling pathway other than PIK3CA were also excluded.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] PIK3CA Mutations PREDICT RESPONSE TO PI3K/AKT/mTOR INHIBITORS
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (03) : 205 - 205
  • [2] Activation of the PI3K/AKT pathway and PIK3CA mutations in Merkel cell carcinoma
    Hafner, C.
    Houben, R.
    Baeurle, A.
    Landthaler, M.
    Becker, J. C.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2010, 8 (09): : 739 - 739
  • [3] Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors
    Janku, F.
    Tsimberidou, A. M.
    Garrido-Laguna, I.
    Hong, D. S.
    Naing, A. M.
    Falchook, G. S.
    Fu, S.
    Luthra, R.
    Wang, X.
    Kurzrock, R.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 83 - 83
  • [4] PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway
    Guan, Ruijuan
    Kang, Zefeng
    Li, Ling
    Yan, Xin
    Gao, Tianpeng
    [J]. PLOS ONE, 2024, 19 (01):
  • [5] PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
    Janku, Filip
    Tsimberidou, Apostolia M.
    Garrido-Laguna, Ignacio
    Wang, Xuemei
    Luthra, Rajyalakshmi
    Hong, David S.
    Naing, Aung
    Falchook, Gerald S.
    Moroney, John W.
    Piha-Paul, Sarina A.
    Wheler, Jennifer J.
    Moulder, Stacy L.
    Fu, Siqing
    Kurzrock, Razelle
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (03) : 558 - 565
  • [6] Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
    Janku, Filip
    Hong, David S.
    Fu, Siqing
    Piha-Paul, Sarina A.
    Naing, Aung
    Falchook, Gerald S.
    Tsimberidou, Apostolia M.
    Stepanek, Vanda M.
    Moulder, Stacy L.
    Lee, J. Jack
    Luthra, Rajyalakshmi
    Zinner, Ralph G.
    Broaddus, Russell R.
    Wheler, Jennifer J.
    Kurzrock, Razelle
    [J]. CELL REPORTS, 2014, 6 (02): : 377 - 387
  • [7] PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
    Janku, Filip
    Wheler, Jennifer J.
    Westin, Shannon N.
    Moulder, Stacy L.
    Naing, Aung
    Tsimberidou, Apostolia M.
    Fu, Siqing
    Falchook, Gerald S.
    Hong, David S.
    Garrido-Laguna, Ignacio
    Luthra, Rajyalakshmi
    Lee, J. Jack
    Lu, Karen H.
    Kurzrock, Razelle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 777 - 782
  • [8] Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
    Payne, Susan
    Depke, Mitchell
    Yueh, Alex
    Sharick, Joseph T.
    Favreau, Peter F.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Skala, Melissa
    Deming, Dustin A.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [9] Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway
    Yan, Wei
    Zhang, Bin
    Wang, Huijun
    Mo, Ran
    Jiang, Xingyuan
    Qin, Wen
    Ma, Lin
    Lin, Zhimiao
    [J]. HEREDITAS, 2021, 158 (01)
  • [10] Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway
    Wei Yan
    Bin Zhang
    Huijun Wang
    Ran Mo
    Xingyuan Jiang
    Wen Qin
    Lin Ma
    Zhimiao Lin
    [J]. Hereditas, 158